Literature DB >> 12426931

Birth defect classification by organ system: a novel approach to heighten teratogenic signalling in a pregnancy registry.

Angela Scheuerle1, Hugh Tilson.   

Abstract

The Antiretroviral Pregnancy Registry (APR) is an ongoing international prospective exposure-registration cohort study that monitors outcomes of pregnancies exposed to marketed antiretroviral medications. The population of women exposed to antiretrovirals remains relatively small, which limits the power of the registry. In order to maximize identification of a teratogenic signal, a special birth defect classification system was devised. Birth defects were organized based upon organ system and embryology, using the Metropolitan Atlanta Congenital Defects Program as a model. Grouping defects that share embryology and pathogenesis increases the likelihood that a teratogenic effect will be apparent. The result is a three-tiered system: organ system, preferred defect term, and reported defect term. This system is text based, which eliminates the need to memorize codes and allows use by anyone familiar with medical terminology. Once established, the new APR Organ System Classification retains enough flexibility that categories may be collapsed or expanded as experience grows. Standardized nomenclature also minimizes variation introduced by collecting defect reports from many different sources.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12426931     DOI: 10.1002/pds.726

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  12 in total

1.  Birth defects among a cohort of infants born to HIV-infected women on antiretroviral medication.

Authors:  D Heather Watts; Sharon Huang; Mary Culnane; Kathleen A Kaiser; Angela Scheuerle; Lynne Mofenson; Kenneth Stanley; Marie-Louise Newell; Laurent Mandelbrot; Jean-Francois Delfraissy; Coleen K Cunningham
Journal:  J Perinat Med       Date:  2010-12-13       Impact factor: 1.901

Review 2.  Pregnancy exposure registries.

Authors:  Dianne L Kennedy; Kathleen Uhl; Sandra L Kweder
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

3.  HCV-HIV coinfected pregnant women: data from a multicentre study in Italy.

Authors:  S Baroncelli; M F Pirillo; R Amici; E Tamburrini; O Genovese; M Ravizza; A Maccabruni; G Masuelli; G Guaraldi; G Liuzzi; C Pinnetti; V Giacomet; A Degli Antoni; A Vimercati; S Dalzero; V Sacchi; Marco Floridia
Journal:  Infection       Date:  2015-10-27       Impact factor: 3.553

4.  Maternal antiretroviral use during pregnancy and infant congenital anomalies: the NISDI perinatal study.

Authors:  Esau C Joao; Guilherme A Calvet; Margot R Krauss; Laura Freimanis Hance; Javier Ortiz; Silvina A Ivalo; Russell Pierre; Mary Reyes; D Heather Watts; Jennifer S Read
Journal:  J Acquir Immune Defic Syndr       Date:  2010-02       Impact factor: 3.731

5.  Pregnant with HIV before age 25: data from a large national study in Italy, 2001-2016.

Authors:  M Floridia; G Masuelli; E Tamburrini; I Cetin; G Liuzzi; P Martinelli; G Guaraldi; A Spinillo; A Vimercati; G Maso; C Pinnetti; V Frisina; S Dalzero; M Ravizza
Journal:  Epidemiol Infect       Date:  2017-08       Impact factor: 4.434

6.  Association between prenatal exposure to antiretroviral therapy and birth defects: an analysis of the French perinatal cohort study (ANRS CO1/CO11).

Authors:  Jeanne Sibiude; Laurent Mandelbrot; Stéphane Blanche; Jérôme Le Chenadec; Naima Boullag-Bonnet; Albert Faye; Catherine Dollfus; Roland Tubiana; Damien Bonnet; Nathalie Lelong; Babak Khoshnood; Josiane Warszawski
Journal:  PLoS Med       Date:  2014-04-29       Impact factor: 11.069

7.  Birth defects in a cohort of infants born to HIV-infected women in Spain, 2000-2009.

Authors:  Luis M Prieto; María Isabel González-Tomé; Eloy Muñoz; María Fernández-Ibieta; Beatriz Soto; Ana Álvarez; Maria Luisa Navarro; Miguel Ángel Roa; José Beceiro; María Isabel de José; Iciar Olabarrieta; David Lora; José Tomás Ramos
Journal:  BMC Infect Dis       Date:  2014-12-24       Impact factor: 3.090

8.  Safety of artemisinins in first trimester of prospectively followed pregnancies: an observational study.

Authors:  Kerryn A Moore; Julie A Simpson; Moo Kho Paw; MuPawJay Pimanpanarak; Jacher Wiladphaingern; Marcus J Rijken; Podjanee Jittamala; Nicholas J White; Freya J I Fowkes; François Nosten; Rose McGready
Journal:  Lancet Infect Dis       Date:  2016-02-08       Impact factor: 25.071

9.  Final results from the Betaseron (interferon β-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events.

Authors:  P K Coyle; S M Sinclair; A E Scheuerle; J M Thorp; J D Albano; M J Rametta
Journal:  BMJ Open       Date:  2014-05-12       Impact factor: 2.692

10.  The Safety of Artemisinin Derivatives for the Treatment of Malaria in the 2nd or 3rd Trimester of Pregnancy: A Systematic Review and Meta-Analysis.

Authors:  Stephanie D Kovacs; Anna Maria van Eijk; Esperanca Sevene; Stephanie Dellicour; Noel S Weiss; Scott Emerson; Richard Steketee; Feiko O Ter Kuile; Andy Stergachis
Journal:  PLoS One       Date:  2016-11-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.